From: Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis
 | No. of studies | Mean difference/risk ratio | 95% CI | P |
---|---|---|---|---|
6-min walk distance | ||||
 Overall | 9 | 53.13 | 25.47, 81.10 | 0.0002 |
 3 months | 6 | 47.92 | 7.95, 87.89 | 0.02 |
 6 months | 8 | 49.68 | 3.34, 96.01 | 0.04 |
 ≥ 12 months | 6 | 63.91 | 0.06, 127.76 | 0.05 |
NYHA functional class | ||||
 Overall | 6 | − 0.48 | − 0.65, − 0.31 | < 0.0001 |
 3 months | 4 | − 0.28 | − 0.49, 0.08 | 0.007 |
 6 months | 4 | − 0.52 | − 0.96, − 0.07 | 0.02 |
 ≥ 12 months | 6 | − 0.63 | − 0.83, − 0.43 | < 0.0001 |
 Peak VO2 | 4 | 0.94 | − 3.15, 5.02 | 0.65 |
 MlHFQ | 4 | − 18.41 | − 29.90, − 6.92 | 0.002 |
 MACE | 6 | 0.79 | 0.60, 1.04 | 0.09 |
 Rehospitalization | 5 | 0.71 | 0.49, 1.04 | 0.08 |
 All-cause mortality | 17 | 0.74 | 0.56, 0.98 | 0.04 |
 Cardiovascular death | 8 | 0.65 | 0.29, 1.46 | 0.29 |